UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Differential diagnosis of suspected multiple sclerosis: a consensus approach

Multiple sclerosis, 2008-11, Vol.14 (9), p.1157-1174

2008

Volltextzugriff (PDF)

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

Multiple sclerosis, 2010-03, Vol.16 (3), p.342-350

2010

Volltextzugriff (PDF)

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

Multiple sclerosis, 2006-06, Vol.12 (3), p.309-320

2006

Volltextzugriff (PDF)

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

Multiple sclerosis, 2008-06, Vol.14 (5), p.663-670

2008

Volltextzugriff (PDF)

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Multiple sclerosis, 2000-08, Vol.6 (4), p.255-266

2000

Volltextzugriff (PDF)

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Multiple sclerosis, 2000-04, Vol.6 (4), p.255-266

2000

Volltextzugriff (PDF)

Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?

Multiple sclerosis, 2009-08, Vol.15 (8), p.959-964

2009

Volltextzugriff (PDF)

The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study

Multiple sclerosis, 1995-11, Vol.1 (3), p.165-169

1995

Volltextzugriff (PDF)

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials

Multiple sclerosis, 2015-09, Vol.21 (10), p.1322-1331

2015

Volltextzugriff (PDF)

Early treatment trials with interferon beta in multiple sclerosis

Multiple sclerosis, 1995, Vol.1 Suppl 1, p.S17-S21

Panitch, H S

1995

Volltextzugriff (PDF)

Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial

Multiple sclerosis, 2002-08, Vol.8 (4), p.330-338

CHAMPS Study Group

2002

Volltextzugriff (PDF)

Alexia without agraphia in multiple sclerosis: case report with magnetic resonance imaging localization

Multiple sclerosis, 2004-12, Vol.10 (6), p.705-707

2004

Volltextzugriff (PDF)

Short-term immunosuppression with mitoxantrone followed by long-term glatiramer acetate vs. glatiramer acetate alone: Results at 36 months in patients with relapsing multiple sclerosis

Multiple sclerosis, 2008-09, Vol.14, p.S29-S293

2008

Volltextzugriff (PDF)

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the I5-year analysis of the US prospective open-label study of glatiramer acetate

Multiple sclerosis, 2010, Vol.16 (3), p.342-350

2010

Volltextzugriff (PDF)

RENEW study update XVIII: ongoing evaluation of the safety and tolerability of mitoxantrone in worsening multiple sclerosis

Multiple sclerosis, 2008-09, Vol.14, p.S175-S175

2008

Volltextzugriff (PDF)

Effect of combined IFNβ-Ia and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis

Multiple sclerosis, 2002-12, Vol.8 (6), p.485-491

2002

Volltextzugriff (PDF)

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

Multiple sclerosis, 2008-09, Vol.14, p.S41-S41

2008

Volltextzugriff (PDF)

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates

Multiple sclerosis, 2001-02, Vol.7 (1), p.33-41

2001

Volltextzugriff (PDF)

Investigational drug therapies for treatment of multiple sclerosis

Multiple sclerosis, 1996-09, Vol.2 (2), p.66-77

Panitch, Hillel S

1996

Volltextzugriff (PDF)

Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis

Multiple sclerosis, 2002-12, Vol.8 (6), p.485-491

2002

Volltextzugriff (PDF)

Effect of combined IFNb-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis

Multiple sclerosis, 2002-12, Vol.8 (6), p.485-491

2002

Volltextzugriff (PDF)

Effect of combined IFN beta -1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis

Multiple sclerosis, 2002-12, Vol.8 (6), p.485-491

2002

Volltextzugriff (PDF)

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group

Multiple sclerosis, 2002-10, Vol.8 (5), p.405-409

CHAMPS Study Group

2002

Volltextzugriff (PDF)

Effect of combined IFN[beta]-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis

Multiple sclerosis, 2002-12, Vol.8 (6), p.485

2002

Volltextzugriff (PDF)

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

Multiple sclerosis, 2000-08, Vol.6 (4), p.255-266

2000

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieMultiple Sclerosis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

Humans
(13)
Clinical Neurology
(11)
Life Sciences & Biomedicine
(11)
Neurosciences
(11)
Neurosciences & Neurology
(11)
Science & Technology
(11)
Biological And Medical Sciences
(10)
Male
(10)
Medical Sciences
(10)
Adult
(9)
Female
(9)
Multiple Sclerosis
(9)
Glatiramer Acetate
(8)
Middle Aged
(8)
Neurology
(8)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(5)
Peptides - Administration & Dosage
(5)
Time Factors
(5)
Treatment Outcome
(5)
Magnetic Resonance Imaging
(4)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

SAGE Journals Online
(25)
MEDLINE
(13)

Zeitschrift / Serie

Multiple Sclerosis Journal
(4)

Menü

Weitere Dienste

Einstellungen

Differential diagnosis of suspected multiple sclerosis: a consensus approach

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?

The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials

Early treatment trials with interferon beta in multiple sclerosis

Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial

Alexia without agraphia in multiple sclerosis: case report with magnetic resonance imaging localization

Short-term immunosuppression with mitoxantrone followed by long-term glatiramer acetate vs. glatiramer acetate alone: Results at 36 months in patients with relapsing multiple sclerosis

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the I5-year analysis of the US prospective open-label study of glatiramer acetate

RENEW study update XVIII: ongoing evaluation of the safety and tolerability of mitoxantrone in worsening multiple sclerosis

Effect of combined IFNβ-Ia and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates

Investigational drug therapies for treatment of multiple sclerosis

Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis

Effect of combined IFNb-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis

Effect of combined IFN beta -1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group

Effect of combined IFN[beta]-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

Aktive Filter

Suchergebnisse filtern